4564 — OncoTherapy Science Cashflow Statement
0.000.00%
Last trade - 00:00- ¥6bn
- ¥5bn
- ¥610m
Annual cashflow statement for OncoTherapy Science, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2,237 | -1,560 | -2,570 | -1,116 | -1,286 |
| Depreciation | |||||
| Non-Cash Items | 28.2 | -79.3 | 538 | 30.8 | 167 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -107 | -172 | -57.4 | 291 | -109 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2,276 | -1,763 | -2,073 | -795 | -1,228 |
| Capital Expenditures | -131 | -43.9 | -457 | -5.39 | -2.63 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 101 | -8.31 | -11 | -14.9 | -30.7 |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -30.7 | -52.2 | -468 | -20.3 | -33.4 |
| Financing Cash Flow Items | — | — | 12.3 | 96 | -11.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2,164 | — | 1,479 | 96 | 671 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -144 | -1,815 | -1,062 | -719 | -590 |